Plain-English translation of NCT05867849 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether (CBD)—a compound derived from cannabis—can help people with bipolar depression who haven't gotten better with standard treatments. You would take the medication (or a matching placebo) for 6 weeks while continuing your current mood-stabilizing medications. The study wants to see if this treatment can reduce depression symptoms and is safe to use.
Many people with bipolar depression don't fully recover with existing medications, leaving them struggling with ongoing symptoms. This trial explores whether this medication might offer additional relief for people in that situation.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for a screening visit, a baseline visit, and then return at weeks 2, 4, and 6 to check how you're doing. Half of participants will receive the medication while half receive a placebo—neither you nor the research team will know which you're getting. You'll continue taking all your current bipolar medications as prescribed, and you'll receive a follow-up phone call 2 weeks after the 6-week study ends to see how you're doing.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Canada